CoRegen closes $93M financing round to enter the clinic and expand its leadership team
Clinical-stage gene therapy biotech CoRegen has secured $93.4 million in a financing round to develop its manufacturing processes, fund its first clinical study and build …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.